Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 04:53 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Study Evaluating The Efficacy And Safety Of Xyntha In Children Less Than 6 Years Of Age
NCT00759655 · Wyeth is now a wholly owned subsidiary of Pfizer · PHASE3 · terminated · last registry update 2022-06-15 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “See termination reason in detailed description.” | – | Registry record, Wyeth is now a wholly owned subsidiary of Pfizer |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against F8 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2023-05-24Results posted on the registry: Bioverativ, a Sanofi company, efanesoctocog alfa (BIVV001) (NCT04161495)
- 2023-04-18Phase 3 first posted: Swedish Orphan Biovitrum, Efanesoctocog alfa (NCT05817812)
- 2023-04-11Results posted on the registry: Margaret Ragni, Eloctate Injectable Product + Emicizumab Injection [Hemlibra] (NCT04303559)
- 2023-04-11Also stopped (terminated): Margaret Ragni, Eloctate Injectable Product + Emicizumab Injection [Hemlibra] (NCT04303559)
- 2023-02-21Results posted on the registry: Margaret Ragni, Eloctate ITI + Emicizumab (NCT04303572)
- 2023-02-21Also stopped (terminated): Margaret Ragni, Eloctate ITI + Emicizumab (NCT04303572)
- 2023-02-09Results posted on the registry: Baxalta now part of Shire, FEIBA (NCT02764489)
- 2023-02-06Results posted on the registry: Genzyme, a Sanofi Company, Fitusiran + BPA prophylaxis (NCT03549871)
- 2023-01-31Phase 3 first posted: Takeda, Adynovate (NCT05707351)
- 2023-01-25Phase 3 first posted: Laboratoire français de Fractionnement et de Biotechnologies, Coagulation Factor VIIa (Recombinant) (NCT05695391)
- 2022-12-22Phase 3 first posted: Sanofi, Fitusiran + Clotting factor concentrates (CFC) or bypassing agents (BPA) (NCT05662319)
- 2022-12-15Results posted on the registry: Hoffmann-La Roche, Emicizumab (NCT04158648)
- 2022-11-10Phase 3 first posted: Pfizer, marstacimab (NCT05611801)
- 2022-10-17Phase 3 first posted: Takeda, Vonicog Alfa + ADVATE (NCT05582993)
- 2022-10-06Phase 3 first posted: Pfizer, a drug against F8 (NCT05568719)
- 2022-06-09Results posted on the registry: Grifols Biologicals, LLC, Alphanate SD/HT (NCT00323856)
- 2022-02-04Results posted on the registry: Genzyme, a Sanofi Company, fitusiran + factor concentrates (NCT03417245)
- 2021-12-21Results posted on the registry: Genzyme, a Sanofi Company, fitusiran + Bypassing agents (NCT03417102)
- 2021-12-07Phase 3 first posted: Bayer, Damoctocog alfa pegol (Jivi, BAY94-9027) (NCT05147662)
- 2021-12-06Phase 3 first posted: Pfizer, PF-06741086 (NCT05145127)
- 2021-11-30Results posted on the registry: Swedish Orphan Biovitrum, Recombinant coagulation factor (rFVIIIFc) (NCT03103542)
- 2021-11-26Results posted on the registry: Novo Nordisk A/S, Turoctocog alfa pegol + Turoctocog alfa pegol (NCT03528551)
- 2021-11-23Results posted on the registry: Grifols Therapeutics LLC, Alphanate (NCT03095287)
- 2021-11-23Also stopped (terminated): Grifols Therapeutics LLC, Alphanate (NCT03095287)
- 2021-10-27Results posted on the registry: CSL Behring, rVIII-SingleChain (NCT02172950)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision